Zydus Lifesciences’ Assertio merger signals a bigger push beyond generics into U.S. oncology
Find out how Zydus Lifesciences’ Assertio merger could reshape its U.S. oncology supportive-care strategy and Rolvedon growth.
Pharma & Biotech
Pharma & Biotech
Acousia Therapeutics’ ACOU085 signal puts Kv7.4 activation in focus for hearing loss prevention
Read how Acousia Therapeutics’ bimokalner Phase 2a signal could reshape cisplatin hearing loss prevention in adults.
Pharma & Biotech
How EOM Pharmaceutical Holdings is positioning EOM613 as a potential multi-cytokine therapy for cancer cachexia
Find out how EOM613 could reshape cancer cachexia treatment as EOM Pharmaceutical Holdings advances its FDA-cleared Phase 2a study.
Pharma & Biotech
Can Assertio give Zydus a faster route into U.S. specialty oncology care?
Zydus gets a U.S. oncology platform, but Rolvedon concentration risk will decide whether the Assertio deal becomes strategic or merely opportunistic.
Pharma & Biotech
Vyome’s VT-1953 Phase 2 data signals breakthrough in malignant fungating wound care
Vyome’s VT-1953 shows strong Phase 2 results in cancer wound care. Find out how this breakthrough could reshape supportive oncology treatment today.
Pharma & Biotech
Assertio-Garda deal analysis: what the Rolvedon-focused takeover means for specialty pharma investors
Find out why Assertio is being sold to Garda Therapeutics and what the Rolvedon-focused deal means for specialty pharma strategy.
Pharma & Biotech
Why Vyome’s VT-1953 data could reshape supportive oncology care in advanced cancer wounds
Vyome’s VT-1953 heads to AACR 2026 with Phase 2 data in malignant fungating wounds. Read what this could change for supportive oncology.
Pharma & Biotech
Why MaaT Pharma’s MaaT013 survival signal could reshape refractory GI-aGvHD treatment debate
MaaT Pharma’s MaaT013 posted pivotal Phase 3 GI-aGvHD data. Read what it could mean for EMA approval, adoption, and microbiome therapeutics.
Pharma & Biotech
Can Hoth Therapeutics’s topical HT-001 redefine EGFR therapy adherence in cancer supportive care?
Hoth’s HT-001 showed 100% response in EGFR therapy toxicity trial. Learn what this means for cancer symptom relief, treatment continuity, and future trials.
Pharma & Biotech
FDA clears mAbxience–Amneal denosumab biosimilars, opening a new front in osteoporosis and oncology pricing
mAbxience and Amneal Pharmaceuticals have secured U.S. Food and Drug Administration (FDA) approval for two denosumab biosimilars, Boncresa and Oziltus, referencing Prolia and XGEVA respectively, clearing a long-anticipated regulatory hurdle in osteoporosis and oncology supportive care. The approvals position Amneal Pharmaceuticals as the exclusive U.S. commercial partner, with mAbxience responsible for development and manufacturing, marking